| Ticker: SIMA | West Kenosia Avenue | |
| Exchange: NASDAQ-National Market | Danbury, Connecticut 06810 | |
| Industry: Manufacturing | (203) 744-4400 |
| Type of Shares: | Common Shares | Filing Date: | 8/31/95 | |
| U.S. Shares: | 1,000,000 | Offer Date: | 2/26/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $6.00 - $7.00 | |
| Primary Shares: | 1,000,000 | Offer Price: | $5.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.50 | |
| Offering Amount: | $6,500,000 | Selling: | $0.25 | |
| Expenses: | $706,750 | Reallowance: | $0.10 | |
| Shares Out After: | 3,500,000 |
| Manager | Tier | Phone |
| Monroe Parker & Company | Lead Manager | (914) 696-4200 |
| Auditor: Grant Thornton | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 6/30/95 | 12/31/95 | 12/31/94 | 12/31/95 | ||
| Revenue: | $8.57 | $4.39 | $3.67 | Assets: | $5.06 |
| Net Income: | $0.56 | $0.15 | -$0.12 | Liabilities: | $1.98 |
| EPS: | $0.22 | $0.05 | -$0.05 | Equity: | $3.08 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company manufactures and sells (i) ultrasound bonding equipment for welding, joining and fastening of thermoplastic components, textiles and other synthetic materials and (ii) ultrasound liquid processors for dispersing, blending, cleaning particles. The Company also has developed and sold and abroad ultrasonic surgical instruments for use in liposuction procedures which substantially liquefy human fat before its removal. In addition, the Company recently commence manufacturing and selling spin welders for plastic parts and is developing devices for vibration welding; these processes do not involve ultrasonic technology. The Company's ultrasonic bonding devices are utilized in the automotive, medical, home entertainment, computer/electronics/electrical, appliance/houseware, textile/apparel, packaging, toy and other industries. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used for research and development of new and existing products, expansion of marketing and sales activities, reduction of bank debt, preparation for compliance with FDA regulatory requirements, purchase and/or lease of new production equipment and working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.